ALTEPLASE

Course overview

ALTEPLASE IS A THROMBOLYTIC AGENT THAT IS MANUFACTURED BY RECOMBINANT DNA TECHNOLOGY. IT IS FDA APPROVED FOR USE IN ACUTE ISCHEMIC STROKE, PULMONARY EMBOLISM, ACUTE MYOCARDIAL INFARCTION, AND OCCLUDED CATHETERS. OFF-LABEL INDICATIONS INCLUDE CATHETER-DIRECTED THROMBOLYSIS IN THE TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE AND DEEP VEIN THROMBOSIS. THIS ACTIVITY OUTLINES THE INDICATIONS, CONTRAINDICATIONS, ACTIVITY, ADVERSE EVENTS, AND TOXICITY OF ALTEPLASE IN THE CLINICAL SETTING AS RELATES TO THE ESSENTIAL POINTS NECESSARY FOR MEMBERS OF AN INTERPROFESSIONAL TEAM MANAGING THE CARE OF PATIENTS IN NEED OF THROMBOLYTIC THERAPY.